Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as when compared with imatinib, for the initial-line cure of CML-CP. Five hundred and nineteen sufferers with recently diagnosed CML-CP were being randomly assigned to get dasatinib at a dose of 100 mg when day-to-day (259 clients) or imatinib https://jolenek665har7.blog2news.com/profile